Journal: Revue des maladies respiratoires
Article Title: [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
PMID/MRN: 27745897
Publication Date: 2016-Oct-13
Abstract:
Targeted therapy in lung cancer changes the prognostic and treatment of patients. MET is an oncogene including exon 14Êmutations and gene amplification associated with worse prognosis. We here report the case of a 47-year-old former smoker, woman, with a stage IV lung adenocarcinoma with multiple chemotherapy failure. A MET amplification was identified and the patient consequently received crizotinib. A major response was observed after eight weeks of treatment. MET amplification screening appears to be interesting with some oncogenic-addicted tumor response rate. Those patients should be enrolled in clinical trials dedicated to tumor with MET alteration.
Copyright © 2016 SPLF. Published by Elsevier Masson SAS. All rights reserved.